DNTH (Dianthus Therapeutics) Shares Buyback Ratio %: -69.90 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $103.87
GF Value $2.87
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Shares Buyback Ratio %?

Dianthus Therapeutics DNTH +2.52% 22 Shares Buyback Ratio % is -69.90 as of Jul. 30, 2026. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.87 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Dianthus Therapeutics's current shares buyback ratio was -69.90%.

Dianthus Therapeutics Shares Buyback Ratio % Related Terms

Dianthus Therapeutics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Shares Buyback Ratio % Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
0.00 0.00 0.00 -109.98 -38.91

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.25 -0.16 -33.19 -0.86 -26.28
DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Shares Buyback Ratio % Calculation

Dianthus Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(31.115 - 43.223) / 31.115
=-38.91%

Dianthus Therapeutics's Shares Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Mar. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(43.223 - 54.583) / 43.223
=-26.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -69.90 mean?
Dianthus Therapeutics (DNTH) has a Shares Buyback Ratio % of -69.90 as of Jul. 30, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Shares Buyback Ratio % too high?
Dianthus Therapeutics' current Shares Buyback Ratio % is -69.90. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Shares Buyback Ratio % compare to SRRK and DFTX?
Dianthus Therapeutics' Shares Buyback Ratio % of -69.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Shares Buyback Ratio % is -69.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.87, compared to a current price of $103.87 — trading 3519.2% above its estimated fair value. The current Shares Buyback Ratio % is -69.90. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Shares Buyback Ratio % is -69.90 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $103.87 is trading 3519.2% above its estimated GF Value™ of $2.87. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Shares Buyback Ratio %: -69.90
  • GF Value™: $2.87 vs. price of $103.87 (3519.2% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$103.87
Price
$2.87
GF Value